• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Celecoxib as Adjunctive Treatment in Acute Mania

Celecoxib as Adjunctive Treatment in Acute Mania

March 1, 2018
Thomas Jordan, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Mousavi et al, J Child Adolesc Psychopharmacol 2017; 27(6):494–500

Emotional stress can trigger an inflammatory cascade response and increase blood levels of proinflammatory cytokines—including IL-1, IL-6, and tumor necrosis factor (TNF-α). These same inflammatory markers intensify in acute episodes of depression and mania. So, would blocking the inflammatory cascade aid in treating acute episodes of mood disorders?

Celecoxib works by selective inhibition of cyclooxygenase-2 and reducing prostaglandin synthesis. The authors of this research demonstrated positive benefit during trials of celecoxib as an adjunctive treatment in adults with acute bipolar mania, obsessive compulsive disorder, and depression. This study explores the safety and efficacy of celecoxib in treating acute mania in adolescents.

This study was an 8-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial conducted at an inpatient psychiatric hospital with 40 adolescents (ages 12–17). The subjects met criteria for a moderate to severe episode of bipolar mania without psychosis. In the treatment protocol, all adolescents received treatment with lithium (target blood level of 0.8–1.1) and risperidone (1 mg per day, then increasing to 3 mg per day). The treatment group also received celecoxib (100 mg twice daily), while the control group received a placebo over an 8-week period. Treatment started in the hospital setting, then continued in an outpatient clinic when the patients were ready for discharge.

The primary outcome was change in the Young Mania Rating Scale (YMRS), measured at baseline and at weeks 2, 4, and 8. At week 8, there was a significant difference in the change in YMRS scores between the celecoxib and control groups (p = 0.04). A secondary outcome measured was the Clinical Global Impressions—Improvement (CGI-I) scale: There was a trend in favor of the celecoxib group that did not reach significance (p = 0.09). For the safety analysis, the most common adverse events reported were increased appetite and dry mouth, but there were no significant differences between the two groups in any of the reported adverse events. Cardiovascular health was also monitored by physical exam and electrocardiogram, which remained normal throughout the study.

CCPR’s take
While the idea of reducing inflammation as part of the treatment regimen for a manic episode shows promise, more research is necessary before recommending use of celecoxib. The data show that celecoxib may be helpful in the acute treatment of a mood episode, but how long should treatment last? Should we follow blood levels of inflammatory markers to guide treatment? What are the risks of longer-term treatment? More studies are needed to answer these questions.
Child Psychiatry
KEYWORDS bipolar_disorder child_psychiatry ocd research-update
Thomas Jordan, MD

Vyvanse for Sluggish Cognitive Tempo in ADHD

More from this author
www.thecarlatreport.com
Issue Date: March 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test for Anxiety - Children and Adolescents, CCPR, March/April 2018
Negative Efficacy of Desvenlafaxine and Fluoxetine for Children and Adolescents With MDD
Note From the Editor-in-Chief
Benzodiazepines in Children and Adolescents
Differentiating ADHD From Anxiety: Tips for Clinicians
Acting Out: Is It Anxiety?
Azithromycin for Acute-Onset Obsessive-Compulsive Disorder in Children
Celecoxib as Adjunctive Treatment in Acute Mania
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.